October 2021

Ushering the New Era in Anti-Drug Antibody Assays with Next Generation Protein Sequencing

2021-10-15T13:30:54-04:00October 15th, 2021|Whitepapers|

Anti-drug antibody (ADA) assays are critical to assess the clinical efficacy and safety of a biological drug and rely on control reagents that mimic the ADA response to the biological drug being tested. These positive controls typically consist of animal-derived pooled polyclonal antibodies or human monoclonal antibody reference panels against the target protein drug.

August 2021

What are Monoclonal Antibodies?

2021-10-12T13:04:45-04:00August 25th, 2021|Articles|

Monoclonal antibodies (mAbs) are homogenous antibodies that bind to a single epitope on an antigen. Kohler and Milstein generated the first mAbs when they developed hybridoma technology in the 1970s. Because of the specificity, homogeneity and unlimited availability, mAbs are valuable reagents used in a variety of important applications including treatment and diagnosis of diseases

July 2021

June 2021

The New Era in ADA Assays

2021-10-05T08:32:34-04:00June 7th, 2021|Webinars|

Anti-Drug Antibody (ADA) assays such as ligand-based assays are critical to assess the clinical efficacy and safety of a biological drug. ADA assays rely on control reagents that mimic the ADA response to the biological drug being tested. These positive controls typically consist of animal-derived (e.g., rabbits) pooled polyclonal antibodies (pAb) [...]

March 2021

The Underlying Cause of Medical Diagnostic Invalidation

2021-10-14T12:30:50-04:00March 23rd, 2021|Whitepapers|

In vitro diagnostics (IVDs) are one of the most commonly used tools to diagnose conditions and guide treatment decisions, and are often considered the “silent champion” of healthcare. They work by detecting the absence or presence of particular markers or by measuring the concentration of analytes or specific substances.